Browse by author
Lookup NU author(s): Professor Mike Waring
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Author(s): Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie W, Pickett SD, Wang J, Wallace O, Weir A
Publication type: Article
Publication status: Published
Journal: Nature Reviews Drug Discovery
Year: 2015
Volume: 14
Pages: 475-486
Online publication date: 19/06/2015
ISSN (print): 1471-0056
ISSN (electronic): 1471-0064
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/nrd4609
DOI: 10.1038/nrd4609
Altmetrics provided by Altmetric
